Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00036933
Status:
COMPLETED
Last Update Posted:
2013-03-25
First Post:
2002-05-13
Brief Title:
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates Plus The Immunological Adjuvant QS21
Status:
COMPLETED
Status Verified Date:
2013-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Vaccines may make the body build an immune response to kill tumor cells Biological therapies such as QS21 use different ways to stimulate the immune system and stop cancer cells from growing Combining vaccine therapy with QS21 may kill more tumor cells
PURPOSE Phase II trial to study the effectiveness of combining vaccine therapy with QS21 in treating patients who have prostate cancer
PURPOSE Phase II trial to study the effectiveness of combining vaccine therapy with QS21 in treating patients who have prostate cancer
Detailed Description:
OBJECTIVES
Determine the safety of glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 in patients with prostate cancer
Determine the antibody response in patients treated with this vaccination therapy
Assess post-immunization changes in PSA levels and other objective parameters of disease radionuclide bone scan in patients treated with this vaccination therapy
OUTLINE Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 subcutaneously once weekly on weeks 0-2 6 14 and 26 in the absence of unacceptable toxicity Patients whose antibody titers against Globo-H or MUC-2 antigens fall below 140 and who have no disease progression may receive a seventh vaccination after week 50
Patients are followed every 3 months for 1 year or until biochemical relapse or radiographic disease progression
Determine the safety of glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 in patients with prostate cancer
Determine the antibody response in patients treated with this vaccination therapy
Assess post-immunization changes in PSA levels and other objective parameters of disease radionuclide bone scan in patients treated with this vaccination therapy
OUTLINE Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 subcutaneously once weekly on weeks 0-2 6 14 and 26 in the absence of unacceptable toxicity Patients whose antibody titers against Globo-H or MUC-2 antigens fall below 140 and who have no disease progression may receive a seventh vaccination after week 50
Patients are followed every 3 months for 1 year or until biochemical relapse or radiographic disease progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA008748 | NIH | None | None |
| MSKCC-01140 | None | None | None |
| NCI-G02-2064 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA008748 |